Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

NCT02607956 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

657

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: DTG
DRUG: F/TAF
DRUG: B/F/TAF
DRUG: DTG Placebo
DRUG: F/TAF Placebo
DRUG: B/F/TAF Placebo

Sponsor

Gilead Sciences